Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxychloroquine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 known ✓ | Q9NR96 | 1/20 | 1.00 |
| ▸ | TLR7 known ✓ | Q9NYK1 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | CGAS | Q8N884 | 1/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxychloroquine SCHEMBL31023589 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL29430237 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL9047 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL30107680 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL8623049 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL29359553 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL8170 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL23854335 | 0.99 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL4204503 | 0.99 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL4742350 | 0.99 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369698-A1 | Treating Dermatological Conditions with Chloroquine and/or Hydroxychloroquine | SPALLITTA FRANK ANTHONY (US) | 2021-12-02 | — | — | US | disclosed |
| WO-2019136225-A1 | TREATING DERMATOLOGICAL CONDITIONS WITH CHLOROQUINE AND/OR HYDROXYCHLOROQUINE | ATTILLAPS HOLDINGS (US) | 2019-07-11 | — | — | WO | disclosed |
| CN-108658858-A | A kind of preparation method of the preparation and process for purification and its sulfate of hydroxychloroquine | 上海中西三维药业有限公司 | 2018-10-16 | — | — | CN | disclosed |
| WO-2013050573-A1 | C-MIP : A BIOMARKER OF LUPUS NEPHRITIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2013-04-11 | — | — | WO | disclosed |
| US-20040197316-A1 | Novel method for the treatment of systemic lupus erythematosus | TSOKOS GEORGE C (US) | 2004-10-07 | — | — | US | disclosed |
| WO-2004071418-A2 | COMPOUNDS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369698-A1 | Treating Dermatological Conditions with Chloroquine and/or Hydroxychloroquine | CUTA, CTSE, HMGCR | TLR9 166/4885TLR7 215/4885CHRM2 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.